First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study
Keyword(s):
Phase 3
◽
Keyword(s):
Keyword(s):
Keyword(s):
2016 ◽
Vol 11
(4)
◽
pp. S117-S118
◽
Keyword(s):